Longwood Fund

PULMOCIDE LIMITED raised $52M on December 6, 2022

Investors: 旭化成ファーマ（株）, Vivo Capital, JEITO, F-Prime Capital Partners, S.R. One Ltd, IP Group plc, SV Life Sciences and Longwood Fund

Photys Therapeutics raised $75M on September 8, 2022

Investors: Heritage Medical Systems, Omega Funds, MPM Capital, 8VC and Longwood Fund

DEM Biopharma, Inc. raised $70M on June 23, 2022

Investors: Astellas Venture Capital L.L.C., UTokyo Innovation Platform Co., Ltd., Insight Partners, Alta Partners, Emerson Collective and Longwood Fund

Carbon Biosciences raised $38M on June 21, 2022

Investors: Astellas Venture Capital L.L.C., Camford Capital, UTokyo Innovation Platform Co., Ltd., Solasta Ventures, Agent Capital and Longwood Fund

Be Biopharma raised $130M on April 14, 2022

Investors: Alta Partners, Takeda UK Limited, Bristol-Myers Squibb, UK, ARCH Venture Partners, Atlas Venture, RA Capital Management, L.P. and Longwood Fund

Rectify Pharma raised $100M on October 14, 2021

Investors: Omega Funds, Atlas Venture, Forbion and Longwood Fund

Axial Therapeutics, Inc. raised $37M on October 13, 2021

Investors: Autism Impact Fund, OneVentures, UTokyo Innovation Platform Co., Ltd., Corundum Systems Biology, Domain Associates and Longwood Fund

Immunitas Therapeutics raised $58M on August 18, 2021

Investors: NS Investment, M Ventures, The Leukemia & Lymphoma Society, Solasta Ventures, Mirae Asset MAPS Global Investments Co., Ltd, Medical Excellence Capital, LLC and Longwood Fund

ImmuneID raised $50M on June 23, 2021

Investors: Section 32, Alta Partners, Tekla Capital Management, Xfund, ARCH Venture Partners, In-Q-Tel and Longwood Fund

PULMOCIDE LIMITED raised $92M on May 27, 2021

Investors: 旭化成ファーマ（株）, IP Group plc, Adjuvant Capital, S.R. One Ltd, F-Prime Capital Partners, JEITO, SV Life Sciences and Longwood Fund